American men and women are living longer than
ever before. The gender disparity in life expectancy is narrowing, as
the increase in longevity among men continues to outpace that among
women. The projected life expectancy of a boy born in 1998 is 73.7
years, almost 2 full years longer than that of a boy born between
1989 and 1991. This rise contrasts with that for baby girls, whose
life expectancy for those born in 1998 is estimated to be 79.3 years,
just half a year higher than that of girls born between 1989 and 1991.
Accompanying these total increases are growing proportions of both
genders over age 64 years. In 1998, close to 11% of men and 14.6% of
women were 65 years of age or older. These proportions are projected
to reach 19% and 21%, respectively, by the middle of the 21st century.
Trends in Incidence of Prostate Disease
As longevity increases, diseases of older ages will also become more
prevalent. Among men, prostate diseases (both benign and malignant)
are expected to continue being the most prominent health concerns for
those over age 50 years. Prostate cancer is principally a disease of
older men, with more than 80% of cases diagnosed in men over 65 years
of age. The age-adjusted incidence rates for prostate cancer
increased some 13% per year between 1984 and 1992, primarily because
of the widespread use of the prostate-specific antigen (PSA) test.
Since peaking in 1993, incidence rates of prostate cancer have
dropped 17% (Figure A). However,
even with this decline and a 10% drop in mortality since 1991,
prostate cancer remains the leading major malignancy among males, and
its mortality is second only to that of lung cancer. The American
Cancer Society estimated that 179,300 men were diagnosed with and
37,000 died from prostate cancer in 1999.
Benign prostatic hyperplasia (BPH), a condition with symptoms very
similar to those for prostate cancer, is even more common. During
1997, BPH diagnoses outnumbered those of prostate cancer in
nonfederal, short-stay hospitals in the United States by 1.85 to 1
(380,000 and 205,000 cases, respectively). As with prostate cancer,
BPH is usually diagnosed in men over age 50 years, with histologic
evidence apparent in more than half of men over 60 years of age and
in about 90% of those age 85 years.
Radical Prostatectomy and TURPWhile less invasive methods of dealing
with BPH and other causes of urinary obstruction continue to be
investigated and developed, surgery (either radical prostatectomy or
transurethral resection of the prostate, [TURP]) remains the
principal treatment for major prostatic problems. The radical (or
open) prostatectomy is more frequently used in cases of localized
prostate cancer and/or for very large prostates, whereas a TURP is
usually performed for benign hyperplasia of the prostate with obstruction.
Both TURPs and open prostatectomies are widely used throughout the
world. Transurethral resections of the prostate remain the most
commonly performed urologic procedure in this country, currently
outnumbering radical prostatectomies by about three to one (Figure
Although TURP is a complex operation, the morbidity and mortality
associated with it continue to be low, and the length of hospital
stay remains significantly shorter than that for a radical
prostatectomy. Since 1987, there has been a general decrease in the
number of TURPs performed in US nonfederal short-stay hospitals but a
fairly steady increase in the number of radical prostatectomies
performed. Transurethral resections of the prostate decreased by
about 59% between 1987 and 1997, dropping from 379,000 to 157,000.
The number of radical prostatectomies, however, increased fourfold
over this period, rising from 13,000 in 1987 to 52,000 in 1997.
Increasing medical/surgical costs, the frequency of these surgeries,
and the debates about the necessity or efficacy of so many TURPs
prompted MetLife researchers to reexamine the issue using 1997 group
health hospital claims data for the procedures. Average charges
associated with both surgeries were investigated from a data set
merged and edited by Corporate Health Strategies, Inc.
The Metropolitan Life Study
More than 603,000 hospital claims records were reviewed from a select
portion of patients covered under MetraHealth Group Health contracts
in 1997. Of these claims, 42% (251,903) were for men, of which 6.2%
were for major diagnostic category (MDC) 11, Diseases/Disorders
of the Kidney and Urinary Tract, and MDC 12,
Diseases/Disorders of the Male Reproductive System. Of
the MDC 12 diagnoses, 35% were for BPH and 16% were for a malignancy.
Over 2,100 radical prostatectomies (defined by CPT codes 55810-55815
and 55840-55845) among men over age 30 years were identified from
these two MDC data sets. In addition, close to 2,200 men over age 30
years had claims for a TURP (CPT code 52601) during the year.
The patients who underwent a TURP were substantially older than the
men who underwent open prostatectomymodal ages of 72 and 63
years, respectively, and median ages of 70 and 61 years. Virtually
all of the radical prostatectomies (99%) were for a malignant
neoplasm of the prostate. Just over three-fourths of the men who had
a TURP procedure were diagnosed with BPH, followed by cancer of the
prostate in another 13%. Data are presented for all states with more
than five procedures but are highlighted and discussed for those in
which 40 or more were performed.
Geographic Variation in Radical Prostatectomy Charges
The average total charge to insurance for a radical prostatectomy in
1997 was $16,990 among 2,149 procedures. Among geographic regions,
the total charges (hospital plus physicians) varied by 35% (Table
1 and Figure
B). However, with the exception of the Pacific region, where
charges were 23% above average, and the three Central regions of the
country, where charges ranged from 6% to 9% below average, the
remaining regional charges tended to be fairly uniform; ie, within
these five regions, the totals differed by less than 4%, either above
or below the average. However, state charges varied more extensively.
There was almost a twofold difference in charges between the states
with the highest and lowest totals, and these states were within the
same region, eg, the Pacific area of the country (Table
1). Within this region, and across the United States as a whole,
the charges in California were the highest, over $23,600, which is
39% above the norm. Washington state reported a total charge almost
half this amount, $12,020 (29% below the US average). Only three
other study states (Illinois, Florida, and New Jersey) had charges
more than 10% above the average, whereas six additional states
(Georgia, Tennessee, Pennsylvania, Indiana, Maryland, and North
Carolina) reported total charges that were 10% or more below the norm.
Hospital ChargesRoom and board plus ancillary fees
comprised the hospital portion of the average total charges and
accounted for 63% of the total bill. This proportion varied from 71%
in California to 52% in Maryland. Hospital charges averaged $10,620
across the country and ranged from $16,740 in California (57% above
the norm) to $7,300 in Maryland and $7,310 in Washingtoneach
31% lower than the United States average.
Ancillary fees (eg, operating room, laboratory fees, pharmacy
charges) averaged $6,760 and accounted for 64% of the total hospital
charge. Their share ranged from 46% in New York and Missouri to 79%
in North Carolina. Ancillary fees over $8,000 (more than 19% above
the norm) were reported in Colorado, New Jersey, California, and
Florida. These fees are contrasted with those reported in Missouri
and New York ($4,640 and $4,630, respectively) each around 31%
below the norm.
The room and board charge averaged $3,860 and ranged from more than
twice that in California ($8,200) to less than half that in North
Carolina ($1,620). This range represented a difference of more than
400% between the high and low charges.
Physicians ChargesSurgical and medical
doctors charges for an open prostatectomy averaged $6,370 and
differed by 44% between states. The highest doctors fees were
reported in New Jersey and New York, each over $8,000 (30% above the
average), whereas in neighboring Pennsylvania (the other state in the
Middle Atlantic region), physicians charges were the
lowest$4,620 (27% below the norm). Three other study states had
physicians fees 10% or more below the normLouisiana,
North Carolina, and Colorado. Illinois was the only other state in
which doctors charges were more than 10% higher than the norm.
Length of StayOn average, a man remained in the hospital
for 3.75 days after a radical prostatectomy. Stays of 4 days or more
were reported in New Jersey, Ohio, Florida, and North Carolina. Men
in Missouri, Maryland, and Minnesota remained hospitalized for 3.28
days or less, which was more than 12% shorter than the average.
Geographic Variation in TURP Charges
The average total charge for a TURP was $6,620over $10,000 less
than for a radical prostatectomy (Table 2).
Once again, the highest regional charges were reported in the
Pacific region ($9,060), where the average was 37% above the norm (Figure
C). The Middle Atlantic region reported the lowest average total
charge, $5,620, 15% below the norm. Three other regional areas had
above-average chargesthe West North Central, Mountain, and West
Variations between states were a bit more pronounced. As with the
open procedures, California led the study states with the highest
total charge$10,170 for a TURP, which is 54% above the norm and
163% higher than Pennsylvanias low charge ($3,860). Minnesota
and Arizona followed Californias high charge with totals over
$8,000 (30% to 28% above the norm). In addition to Pennsylvania,
three other states, Ohio, Michigan, and North Carolina, reported
total charges 20% or more below the US average, ranging between
$5,260 and $4,700.
Hospital ChargesOn average, more than two-thirds (68%)
of the total charge was accounted for by the hospital chargeroom
and board plus ancillary fees. This proportion ranged from 75% of
the total in California and Arizona to 57% in Ohio. On average, the
hospital charge was $4,490 but differed by almost 200% between study
states. California, with its average of $7,600, was 69% above the
norm and 193% above the low hospital charge reported in Pennsylvania
($2,590). Arizona and Minnesota had the second and third highest
hospital charges, 42% and 41%, respectively, above the average. At
the other end of the scale were Ohio and North Carolina, with
hospital charges less than $3,000, 33% and 37%, respectively, below
the United States norm.
Ancillary fees comprised 63% of the hospital charge and averaged
$2,810 across the country. This proportion varied extensively,
however, ranging from 80% and 81%, respectively, in Tennessee and
North Carolina to 48% in Ohio. Ancillary fees were highest in
Minnesota, Florida, and California, ranging from 67% to 32% above
average and were lowest in Pennsylvania and Ohio, 41% and 49% below
Room and board fees averaged $1,690, with the highest charge again
reported in California, 130% above the norm and more than seven times
the low charge in North Carolina. Neighboring Arizona reported the
second highest room and board charge, also over $3,000 and 89% above
the US average. In addition to North Carolina, Pennsylvania,
Wisconsin, and Tennessee each had room and board fees more than 40%
below the norm.
Physicians ChargesOn average, the physicians
charges for a TURP were $2,130. New Jersey, New York, and California
each had doctors fees more than 20% above this average and more
than twice the low charge in Pennsylvania. Physicians charges
between 10% and 20% below the average were also reported in North
Carolina and Michigan.
Length of StayAverage length of hospitalization for a
TURP in 1997 was 2.80 days. This stay ranged from 3.25 days in the
Middle Atlantic region to 2.27 days in both the Mountain and Pacific
regions. New Jersey and New York had the longest hospitalizations,
3.51 and 3.31 days, respectively; Minnesota had the shortest among
the study states, 2.14 days.
The noted variations in charges for and distribution of
prostatectomies and TURPs remain perplexing. Even as the charges
decrease and length of stay is shortened, these surgeries are
expensive, consuming a substantial proportion of the health care
resources in the United States. Whether the noted differences reflect
varying practice patterns, cultural predilections, patient
preferences, socioeconomic factors, or lack of consensus about
optimal care for and/or early detection and management of prostate
diseases are issues to be studied further.
Clearly, the male population in the United States is aging. Estimates
are that, by the year 2020, one in six American men (a projected 23.8
million) will be over age 65.18 years. With the growing number of
older men, it seems prudent to direct attention and increase efforts
to developing efficacious, less invasive, and less expensive
treatment for prostate diseases.